|
Molecular properties generated using the CDK |
Classification ![]() |
|
Compound class | Synthetic organic |
IUPAC Name ![]() |
(E)-N-[(1R)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-3-[2-propyl-6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide |
International Nonproprietary Names ![]() |
|
INN number | INN |
10566 | asivatrep |
Synonyms ![]() |
Example 230 [US7858621] | PAC-14028 |
Comments |
Asivatrep (PAC-14028) is an antagonist of the transient receptor potential vanilloid type 1 (TRPV1) channel, developed by AmorePacific for anti-inflammatory potential in refractory dermatoses [2]. It is claimed as example 230 in patent US7858621 [1]. PAC-14028 is administered topically for skin inflammation. |
Database Links ![]() |
|
CAS Registry No. | 1005168-10-4 (source: WHO INN record) |
ChEMBL Ligand | CHEMBL3707398 |
GtoPdb PubChem SID | 340590251 |
PubChem CID | 56649347 |
Search Google for chemical match using the InChIKey | UKGJZDSUJSPAJL-YPUOHESYSA-N |
Search Google for chemicals with the same backbone | UKGJZDSUJSPAJL |
Search PubMed clinical trials | asivatrep |
Search PubMed titles | asivatrep |
Search PubMed titles/abstracts | asivatrep |
Search UniChem for chemical match using the InChIKey | UKGJZDSUJSPAJL-YPUOHESYSA-N |
Search UniChem for chemicals with the same backbone | UKGJZDSUJSPAJL |